Transcriptional repression by androgen receptor: Roles in castration-resistant prostate cancer

Galina Gritsina, Wei Qiang Gao, Jindan Yu*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Androgen receptor (AR), a hormonal transcription factor, plays important roles during prostate cancer progression and is a key target for therapeutic interventions. While androgen-deprivation therapies are initially successful in regressing prostate tumors, the disease ultimately comes back as castration-resistant prostate cancer (CRPC) or at the late stage as neuroendocrine prostate cancer (NEPC). CRPC remains largely dependent on hyperactive AR signaling in the milieu of low androgen, while NEPC is negative of AR expression but positive of many AR-repressed genes. Recent technological advances in genome-wide analysis of transcription factor binding sites have revealed an unprecedented set of AR target genes. In addition to its well-known function in activating gene expression, AR is increasingly known to also act as a transcriptional repressor. Here, we review the molecular mechanisms by which AR represses gene expression. We also summarize AR-repressed genes that are aberrantly upregulated in CRPC and NEPC and represent promising targets for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)215-223
Number of pages9
JournalAsian Journal of Andrology
Issue number3
StatePublished - May 1 2019


  • Androgen receptor
  • CRPC
  • EZH2
  • Histone modifications
  • NEPC
  • Targeted therapy
  • Transcriptional repressor

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Transcriptional repression by androgen receptor: Roles in castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this